Your browser doesn't support javascript.
loading
Metalloimmunotherapy with Rhodium and Ruthenium Complexes: Targeting Tumor-Associated Macrophages.
Toupin, Nicholas; Herroon, Mackenzie K; Thummel, Randolph P; Turro, Claudia; Podgorski, Izabela; Gibson, Heather; Kodanko, Jeremy J.
Afiliación
  • Toupin N; Department of Chemistry, Wayne State University, 5101 Cass Ave, Detroit, MI 48202, USA.
  • Herroon MK; Department of Pharmacology, School of Medicine, Wayne State University, Detroit, MI 48201, USA.
  • Thummel RP; Department of Chemistry, University of Houston, Houston, Texas 77204-5003, USA.
  • Turro C; Department of Chemistry and Biochemistry, The Ohio State University, Columbus, Ohio 43210, USA.
  • Podgorski I; Department of Pharmacology, School of Medicine, Wayne State University, Detroit, MI 48201, USA.
  • Gibson H; Karmanos Cancer Institute, Detroit, Michigan 48201, USA.
  • Kodanko JJ; Department of Oncology, Wayne State University, Detroit, MI 48201, USA.
Chemistry ; 28(24): e202104430, 2022 Apr 27.
Article en En | MEDLINE | ID: mdl-35235227
Tumor associated macrophages (TAMs) suppress the cancer immune response and are a key target for immunotherapy. The effects of ruthenium and rhodium complexes on TAMs have not been well characterized. To address this gap in the field, a panel of 22 dirhodium and ruthenium complexes were screened against three subtypes of macrophages, triple-negative breast cancer and normal breast tissue cells. Experiments were carried out in 2D and biomimetic 3D co-culture experiments with and without irradiation with blue light. Leads were identified with cell-type-specific toxicity toward macrophage subtypes, cancer cells, or both. Experiments with 3D spheroids revealed complexes that sensitized the tumor models to the chemotherapeutic doxorubicin. Cell surface exposure of calreticulin, a known facilitator of immunogenic cell death (ICD), was increased upon treatment, along with a concomitant reduction in the M2-subtype classifier arginase. Our findings lay a strong foundation for the future development of ruthenium- and rhodium-based chemotherapies targeting TAMs.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Rodio / Rutenio / Neoplasias de la Mama Triple Negativas Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Chemistry Asunto de la revista: QUIMICA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Rodio / Rutenio / Neoplasias de la Mama Triple Negativas Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Chemistry Asunto de la revista: QUIMICA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Alemania